Approximately 20% of breast cancers overexpress the Erb-b2 receptor tyrosine kinase 2 also known as the Human Epithelial Growth Receptor 2 or Neu oncogene (ERBB2/HER2/neu), usually through amplification of the ERBB2 gene. This evidence concerns the gene ERBB2 and breast carcinoma.